![\"Analysts](\"https:\/\/s.yimg.com\/ny\/api\/res\/1.2\/sn7cssG2DkEideS1zqwEJg--\/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2Ng--\/https:\/\/d29szjachogqwa.cloudfront.net\/images\/user-uploaded\/screenshot_2026-04-12_at_11.31.28%E2%80%AFpm_2901.png\")
<\/div>\n<\/div>Johnson & Johnson first quarter profit beats estimates as Stelara faces competition<\/h2>\n\nJohnson & Johnson (JNJ) stock dipped in premarket trading on Tuesday<\/p>\n
In the first quarter, JNJ reported adjusted earnings per share of $2.70, beating Wall Street estimates of $2.68. Revenue of $24 billion also came in ahead of expectations of $23.6 billion.<\/p>\n
The company raised its full-year earnings per share guidance slightly to $11.45\u2013$11.65, with a midpoint in line with estimates.<\/p>\n
JNJ said that growth was primarily driven by its cancer drug Darzalex and \u200cpsoriasis treatment Tremfya, which helped offset an approximate 920 basis point hit to its immunology drug Stelara as new entrants came to market following the expiration of JNJ\u2019s patent.<\/p>\n
Reuters reports:<\/p>\n
Read more here.<\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n- \n\n\n\n\n
BlackRock beats earnings, revenue estimates in one of its ‘strongest starts’<\/h2>\n\nBlackRock (BLK) stock climbed 2% in premarket trading after the world\u2019s largest asset manager reported its assets under management rose 20% year over year to $13.8 trillion.<\/p>\n
Adjusted net income rose 17% to $2.07 billion, and revenue rose 27% to $6.7 billion, topping estimates of $6.4 billion forecast by Wall Street analysts.<\/p>\n
Adjusted earnings per share of $12.53 also beat expectations of $11.50, according to S&P Global Market Intelligence.<\/p>\n
\u201cBlackRock delivered one of the strongest starts to a year in our history,” BlackRock CEO and Chairman Larry Fink said in the release.<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n
- \n\n\n\n\n
JPMorgan profits rise 13% as Dimon warns of ‘increasingly complex set of risks’<\/h2>\n\nYahoo Finance\u2019s David Hollerith reports:<\/p>\n
Read more here.<\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n- \n\n\n
Johnson & Johnson (JNJ) stock dipped in premarket trading on Tuesday<\/p>\n
In the first quarter, JNJ reported adjusted earnings per share of $2.70, beating Wall Street estimates of $2.68. Revenue of $24 billion also came in ahead of expectations of $23.6 billion.<\/p>\n
The company raised its full-year earnings per share guidance slightly to $11.45\u2013$11.65, with a midpoint in line with estimates.<\/p>\n
JNJ said that growth was primarily driven by its cancer drug Darzalex and \u200cpsoriasis treatment Tremfya, which helped offset an approximate 920 basis point hit to its immunology drug Stelara as new entrants came to market following the expiration of JNJ\u2019s patent.<\/p>\n
Reuters reports:<\/p>\n
Read more here.<\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n BlackRock (BLK) stock climbed 2% in premarket trading after the world\u2019s largest asset manager reported its assets under management rose 20% year over year to $13.8 trillion.<\/p>\n Adjusted net income rose 17% to $2.07 billion, and revenue rose 27% to $6.7 billion, topping estimates of $6.4 billion forecast by Wall Street analysts.<\/p>\n Adjusted earnings per share of $12.53 also beat expectations of $11.50, according to S&P Global Market Intelligence.<\/p>\n \u201cBlackRock delivered one of the strongest starts to a year in our history,” BlackRock CEO and Chairman Larry Fink said in the release.<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n Yahoo Finance\u2019s David Hollerith reports:<\/p>\n Read more here.<\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\nBlackRock beats earnings, revenue estimates in one of its ‘strongest starts’<\/h2>\n
JPMorgan profits rise 13% as Dimon warns of ‘increasingly complex set of risks’<\/h2>\n